CVS Decision to Stop Tobacco Sales Reduced Cigarette Purchase
The company's study has found a 38% drop in cigarette purchase among shoppers who visit CVS stores.
In 2014, pharmacy giant and healthcare company CVS Health decided to
The authors mined household purchasing data for the period between September 2014 and August 2015 for 3 groups:
- CVS-exclusive cigarette purchasers
- CVS+ (CVS and other retailers)
- Other exclusive (only non-CVS retailers)
Using point-of-sale purchase data from 13 states, the authors compared cigarette purchases for the period before CVS implemented its policy (January 2012 to August 2014) and for the period right after (September 2014 to April 2015). In the chosen states, CVS had a market share of at least 15%; 3 control states used in the analyses had no CVS stores.
The results showed that shoppers at CVS stores were 38% more likely (95% CI, 1.06-1.81) to stop buying cigarettes, compared with shoppers in the comparator groups. Further, the 13 states saw a mean reduction of 0.14 packs per month for a single smoker (95% CI, 0.06-0.22).
Troyen A. Brennan, MD, chief medical officer of CVS Health, highlighted the public health impact of the CVS decision made in 2014. “When we removed tobacco from our shelves, a significant number of our customers simply stopped buying and hopefully smoking cigarettes altogether instead of just altering their cigarette purchasing habits,” he
None of the company’s rivals—Wal-Mart, Rite Aid, or Walgreens—have followed in CVS’ footsteps.
Meanwhile, CVS continues to invest further in its public policy efforts with respect to tobacco use. The company's Be The First initiative,
CVS has also partnered with the American Cancer Society to grant $3.6 million to college campuses throughout the country in an effort to advocate, adopt, and implement a tobacco-free campus policy.
Reference
Polinski JM, Howell B, Gagno MA, et al. Impact of CVS Pharmacy’s discontinuance of tobacco sales on cigarette purchasing (2012—2014) [published online February 16, 2017]. Am J Public Health. doi:10.2105/AJPH.2016.303612.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025